Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Review on Bortezomib Resistance in Multiple Myeloma and Potential Role of Emerging Technologies
Gül Kozalak, İsmail Bütün, Erçil Toyran, et al.
Pharmaceuticals (2023) Vol. 16, Iss. 1, pp. 111-111
Open Access | Times Cited: 17

Showing 17 citing articles:

miRNAs driving diagnosis, progression, and drug resistance in multiple myeloma
Mohamed A. Elkady, Amr Mohamed Yehia, Elsayed G.E. Elsakka, et al.
Pathology - Research and Practice (2023) Vol. 248, pp. 154704-154704
Closed Access | Times Cited: 28
Ubiquitin–proteasome system as a target for anticancer treatment—an update
Yeon‐Jung Kim, Yeonjoo Lee, H. Y. Shin, et al.
Archives of Pharmacal Research (2023) Vol. 46, Iss. 7, pp. 573-597
Closed Access | Times Cited: 21
Prognostic Value of PSMB5 and Correlations with LC3II and Reactive Oxygen Species Levels in the Bone Marrow Mononuclear Cells of Bortezomib-Resistant Multiple Myeloma Patients
Eva Plakoula, Georgios Kalampounias, Spyridon Alexis, et al.
Current Issues in Molecular Biology (2025) Vol. 47, Iss. 1, pp. 32-32
Open Access
Comparative Analysis of Acquired Resistance to Bortezomib in Prostate Cancer Cells Using Proteomic and Bioinformatic Tools
Semih Şeker, Betül Şahin, Azmi Yerlikaya
Journal of Cellular and Molecular Medicine (2025) Vol. 29, Iss. 1
Open Access
ER Stress-Activated HSF1 Governs Cancer Cell Resistance to USP7 Inhibitor-Based Chemotherapy through the PERK Pathway
Chang-Hoon Lim, Xue-Quan Fang, Hyeji Kang, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 5, pp. 2768-2768
Open Access | Times Cited: 2
Different Strategies to Overcome Resistance to Proteasome Inhibitors—A Summary 20 Years after Their Introduction
Paweł Tyrna, Grzegorz Procyk, Łukasz Szeleszczuk, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 16, pp. 8949-8949
Open Access | Times Cited: 2
Design and discovery of novel dipeptide boronic acid ester proteasome inhibitors, an oral slowly-released prodrug for the treatment of multiple myeloma
Xueyuan Wang, Wen Zhang, Tiantian Wen, et al.
European Journal of Medicinal Chemistry (2023) Vol. 250, pp. 115187-115187
Closed Access | Times Cited: 7
Autophagy-related mechanisms for treatment of multiple myeloma
Gül Kozalak, Ali Koşar
Cancer Drug Resistance (2023), pp. 838-57
Open Access | Times Cited: 5
Development of small molecule–drug conjugates based on derivatives of natural proteasome inhibitors that exhibit selectivity for PSMA-expressing cancer cells
T. Obara, N. Kawano, Kengo Tatsumi, et al.
Bioorganic & Medicinal Chemistry (2024) Vol. 108, pp. 117773-117773
Closed Access | Times Cited: 1
Stability and potential degradation of the α′,β′-epoxyketone pharmacophore on ZnO nanocarriers: insights from reactive molecular dynamics and density functional theory calculations
Cheherazade Trouki, Susanna Monti, Giovanni Barcaro
Journal of Materials Chemistry B (2023) Vol. 11, Iss. 25, pp. 5870-5881
Open Access | Times Cited: 3
Synergistic Effect of a Combination of Proteasome and Ribonucleotide Reductase Inhibitors in a Biochemical Model of the Yeast Saccharomyces cerevisiae and a Glioblastoma Cell Line
Kirill A. Kulagin, Elizaveta Starodubova, Pamila J. Osipova, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 7, pp. 3977-3977
Open Access
The SAR analysis of dietary polyphenols and their antagonistic effects on bortezomib at physiological concentrations
Trương Thị Bạch Vân, Hsun‐Shuo Chang, Ho‐Cheng Wu, et al.
Frontiers in Pharmacology (2024) Vol. 15
Open Access
Circular RNA_0003489 reflects unfavorable treatment response and shortened survival in newly diagnosed multiple myeloma patients who receive bortezomib-based induction therapy
Senhua Song, Junjie Xie, Biao Xu, et al.
Hematology (2024) Vol. 29, Iss. 1
Open Access
New Era Treatment Modalities for Hematologic Cancers
Gül Kozalak, Nazente Atçeken
Interdisciplinary cancer research (2024)
Closed Access
Epigenetic Alterations in Multiple Myeloma and Potential Therapy Approaches
Gül Kozalak, Nazente Atçeken
Interdisciplinary cancer research (2024)
Closed Access
Doxorubicin synergizes bortezomib-induced multiple myeloma cell death by inhibiting aggresome formation and augmenting endoplasmic reticulum/Golgi stress and apoptosis
Chang‐Tze Ricky Yu, Yuting Liao, Chi-Yin Nina Chiang, et al.
Journal of Translational Medicine (2024) Vol. 22, Iss. 1
Open Access
The quantification of circular RNA 0007841 during induction therapy helps estimate the response and survival benefits to bortezomib-based regimen in multiple myeloma
Yigang Guo, X. Feng, Zhen Wang, et al.
Irish Journal of Medical Science (1971 -) (2023) Vol. 193, Iss. 1, pp. 17-25
Closed Access | Times Cited: 1
Page 1

Scroll to top